Central Portalization Correlates with Fibrosis but Not with Risk Factors for Nonalcoholic Steatohepatitis in Steatotic Chronic Hepatitis C

Table 1

Clinical data, steatosis, and fibrosis of steatotic HCV (>10% steatosis) study group and two control groups— by Fisher’s exact test, statistically significant; the information regarding risk factors was unavailable or incomplete in 9 patients of the study group. ^#HCV genotype was known in 44 cases in the study group and 17 cases in HCV control group. M: male; F: female; DM: diabetes mellitus; obesity: body mass index (BMI) of ≥30 kg/m²; n/a: not applicable; Ishak: Ishak’s fibrosis staging system [35]; NASH CRN: NASH Clinical Research Network’s fibrosis staging system for NASH [36].

	Study group	Control group
	HCV with >10% steatosis	HCV with ≤10% steatosis	NASH, no HCV
Number of cases	65	20	22
Age	48	47	43
M : F	49 : 16	17 : 3	13 : 9
Type 2 DM	14 (22%)	1 (5%) ()	5 (23%) ()
Obesity	33 (51%)	5 (25%) ()	20 (91%) ()
Alcohol	32 (49%)	8 (40%) ()	4 (18%) ()
HCV genotype^#
1a/1b	34 (77%)	17 (100%) ()	n/a
2a/2b	3 (7%)	0 ()	n/a
3	7 (16%)	0 ()	n/a
Steatosis
<33%	22 (34%)	20 (100%)	10 (46%) ()
33–66%	30 (46%)	0	3 (14%) ()
>66%	13 (20%)	0	9 (41%) ()
Fibrosis	Ishak	Ishak	NASH CRN
	0–2: 23 (35%)	0–2: 13 (65%) ()	0-1: 14 (64%)
	3-4: 23 (35%)	3-4: 6 (30%) ()	2: 4 (18%)
	5-6: 19 (29%)	5-6: 1 (5%) ()	3: 2 (9%)
			4: 2 (9%)